I should have mentioned she is the Senior Director, Investor Relations & Corporate Communications. This was the first time I had called IR and was very impressed with how she handled my call.
I talked to Lisa Caparelli this morning, she answered the call directly (number listed on website), while she can't release names she did indicate that approximately 80% of the new share purchases were by institutions, long term holders. She also pointed me to two presentations at investor conferences that are on the website. Their molecule is synthetic and has been modified so it cannot convert back to prednisone which would be harmful to the body. So, it has no hormonal side effects (a risk for SAGE's compound).
Aren't we glad to have stayed busy buying all those shares the market put on sale under $3.00 and since then under $3.40! Even now, with the stage set for the New Era for Idera, $4.00 shares will seem low going forward, as we head into double digits.
Amano, On Dec 2, 2014 there was a PR from Idera on IMO-2055 as to its preclinical data used in combination with ipilimumab. I find no update or recent mention of this compound or for that matter IMO-3100 they used in the psoraisis trial. Do you have anything on this, I was going to call Doody and ask him, maybe that's next.
Anybody here think MIlano doesn't have the goods already in hand? Confidence exudes here, you don't need to watch unless for fun, you can lock away your shares and come back in several years to open your 10-bagger.
I too added on Wednesday. When the market misprices a great stock this considerably, it's my pleasure to add to my position. It's ready to explode.
You might as well just give a green thumb. Taking credit for being a 'thought leader' after others have posted their thoughts is not becoming nor does it raise your credibility. As to bio being PCF, I remember his posts, but he disappeared. Not important to know. Bio has credibility here, what's past is over in my mind.
Thanks for posting your targets and summary. We are chock full of potential here, maybe Martin Shkreli will announce he's buying in? No gimmicks here, just solid science and great management. O/T check out MRNS.
While you are correct that a GC is bullish, you are incorrect that is happening on our chart. A death cross occurs when the 50-day simple moving average crosses below the 200-day moving average. That is about to happen, but I don't put any consequence to it, our metrics call for a rising stock price.
You know Chris Garabedian resigned last April, and the stock has tripled since then. He had problematic relations in the Company's dealing with the FDA, so meanwhile their CMO Ed Kaye, MD, is acting as temporary CEO until a permanent replacement CEO is hired. They left Seattle some time ago but still have an outpost in Oregon.
There's a lot of us here who have these targets and aspirations. I am way heavy in this and HZNP, both being diversified in their broad approach and both being invested in the future of medicines for orphan disease, I like my chances. Good luck and thanks for the comments.
That post was about 'JPM must be getting the word out to their clients' (Nov 27, 2015 12:24 PM by the_quintupler). He's been invested here since January 2014, and investing for 25 years. He has this and three others he's invested in, says he's going to hold for it to reach maturation of their platforms, mentioning a high 20's target. He makes good points.
From the New Idera website:
Preclinical data support initiating clinical development of a TLR antagonist candidate in DMD.
TLR antagonism represents a non-steroidal anti-inflammatory
therapeutic approach applicable to all patients with DMD regardless
of dystrophin genotype
– TLRs are key drivers of muscle inflammation and are over-activated
in DMD patients at all stages of the disease
• Improved skeletal and cardiac muscle function was observed in
~1-year-old mdx mice with double MYD88 knockout, demonstrating
the role of the TLR pathway in the disease process
• An investigational TLR antagonist improved muscle inflammation,
cytokine gene expression, markers of muscle damage and immune
activation, and EDL muscle function following five weeks of treatment
in mdx mice
• Collectively, these data support advancing IMO-8400, an investigational
antagonist of TLRs 7, 8 and 9, into clinical development for the
treatment of DMD patients
I couldn't agree more with the point you make here, there's good reason to be excited. As a foot note to my post last week on this subject, Biomarin's Drisapersen got slammed in the Adcomm meeting last Tuesday, it now appears as though Sarepta's eteplirsen is going to be the sole survivor of the "Biotech Battle" for DMD therapy. As they progress, you can bet there will be a spotlight on what Idera is doing as there is a lot of attention focused now on DMD.
Today's Barron's follow up article 'Rival's Woes Bode Well for Sarepta' quoted "Sarepta still has lots of upside potential because a family of DMD drugs could generate over $3 billion of US revenues plus similar sales abroad". Barron's goes on further to say "Our bet is that the FDA will approve eteplirsen given clinical and safety data and what is likely to be a strong support from patients and families at an advisory committee meeting on Jan. 22. That will be followed by an FDA approval decision by Feb.26."
Idera's TLR approach is fresh, no one else has tried it as yet. From what I've heard, Idera's molecule may result in a combination therapy, compatible with eteplirsen or others, it wouldn't have to necessarily be a competitive or stand alone therapy.
How do you know this to be true, that their shares are borrowed by short sellers? I agree with your point in concept, just wondering how you know this to be true?
My last IDRA share buy was at 3.26 on November 20th, which topped off my position. Today I purchased some shares in Foundation Medicine FMI which is owned 56.3% by Roche yet operates independently. "Oncology major Roche (RHHBY) recently announced that it has entered into a strategic collaboration agreement to acquire up to a 56.3% stake in Foundation Medicine, Inc. (FMI), a molecular information and genomic analysis company, on a fully diluted basis through a tender and acquisition of newly issued shares." That was January 14th.
It was at lows earlier this week, I've been following it (never owned it before) and went over their ER transcript in detail this week. I think it's vastly undervalued, since Roche added their $1B investment this year at $50 a share.
Thanks for sharing your picks, IDRA is my largest position and I intend to hold like you, for the growth we all see here.